Breakthrough in the European Weight-Loss Market

On August 10, Eli Lilly and Company’s weight-loss pill Foundayo won approval in the UK, becoming the first country in Europe to clear the drug for both weight management and type 2 diabetes. This significant milestone marks the beginning of a new era in the European weight-loss market, with Foundayo poised to challenge Novo Nordisk A/S’s dominant position.

Foundayo’s approval in the UK is a crucial step forward for Eli Lilly and Company, as the company looks to close the gap with Novo Nordisk A/S in the European weight-loss market. With its convenience edge, Foundayo offers patients the flexibility to take the pill at any time of day without food or water restrictions, a significant advantage over Novo Nordisk A/S’s Wegovy pill, which must be taken on an empty stomach with a 30-minute wait before eating.

The UK approval is a significant boost to Eli Lilly and Company’s revenue guidance, with the company now expecting to generate $85 billion to $87 billion in revenue in 2026, up from its earlier forecast. Foundayo’s strong sales performance in the US, with the drug generating $98 million in sales last quarter, is also a key factor in the company’s revised revenue guidance.

The Bull and Bear Case: Eli Lilly and Company

While Foundayo’s convenience edge is a significant advantage, Novo Nordisk A/S’s Wegovy pill has already gained traction in the UK market, with over 300,000 patients starting treatment within the first three weeks of its launch. The Wegovy pill has also secured a positive recommendation from the European Union, giving it a head start in the European market.

The competition between Eli Lilly and Company and Novo Nordisk A/S is heating up, with Novo Nordisk A/S suing Eli Lilly and Company over allegedly deceptive advertising. The rivalry between the two companies is likely to continue, with both companies vying for market share in the European weight-loss market.

The Bull and Bear Case: Novo Nordisk A/S

Novo Nordisk A/S’s Wegovy pill has already topped 5 million prescriptions since its launch in January, with the company expecting strong sales growth in the coming quarters. The Wegovy pill’s success is a testament to Novo Nordisk A/S’s expertise in the weight-loss market, with the company’s second-quarter sales rising 3% in constant currency to 78.49 billion kroner.

However, Novo Nordisk A/S’s sales of Wegovy pills in the second quarter fell short of analysts’ expectations, with the company citing tougher competition and lower realized prices tied to its pricing deal with the Trump administration. The company’s updated guidance flagged a coming decline in its US business, a development that is likely to impact its stock price.

The competition between Eli Lilly and Company and Novo Nordisk A/S is likely to continue, with both companies vying for market share in the European weight-loss market. While Novo Nordisk A/S has a head start, Eli Lilly and Company’s Foundayo pill is poised to challenge its dominance, making the European weight-loss market an exciting space to watch.